The Monthly and Yearly performances are -26.45 percent and -67.14 percent respectively. The stock has lost -76.86% in the past month, -81.62% in the previous three months, and -80.10% on an YTD basis.
Valeant ended Thursday's session with a gain of 0.19 at $11.20. The difference between Actual EPS and Estimated EPS was 0.05 Percent. Stock has got OUTPERFORM rating from 3 analysts of Thomson Reuters, 18 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating.
That trade followed on the heels of a CNBC report on Monday that billionaire hedge fund manager Bill Ackman exited the embattled pharmaceutical company, liquidating his 27.2 million share stake.
Jewish Community Center here among those receiving bomb threats Wednesday
No bomb was found and it was a "non-credible threat", according to Officer Mark Stevens of the Dunwoody Police Department. The senators also raised concerns about the desecration of hundreds of headstones at Jewish cemeteries in St.
Several sell side analysts reviewed their recommendations on Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) yearly performance is -84.23% and net profit margin is -24.90%. The Stock now has the market capitalization of $3.85 Billion, P/E (price to earnings ttm) of 0 and Weekly volatility of 5.58% and monthly volatility of 6.01% respectively. The stock was acquired at an average price of $14.73 per share, for a total transaction of $73,650.00. Institutional investors own 64.34% of the company's stock. Analyst's mean target price for VRX is $21.34 while analysts mean recommendation is 3.00. The company's past year sales total was 2.37 Billion. The company's market cap is $3.83 billion. The firm earned $2.40 billion during the quarter, compared to the consensus estimate of $2.34 billion. The Company's shares are trading -72.85% below their 50-day moving average and -93.67% below their 200-day moving average. BTIG Research restated a "neutral" rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, January 11th. The firm's revenue for the quarter was down 12.9% compared to the same quarter past year. According to them, the median (average) EPS the company could deliver is 0.91/share. Morgan Stanley raised its position in Valeant Pharmaceuticals Intl by 241.6% in the third quarter. Rock Springs Capital Management LP now owns 68,600 shares of the specialty pharmaceutical company's stock worth $1,684,000 after buying an additional 2,500 shares during the last quarter. Frontier Wealth Management LLC bought a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth $149,000. Finally, Private Advisor Group LLC raised its stake in Valeant Pharmaceuticals Intl by 23.2% in the fourth quarter. Finally, Hexavest Inc. raised its position in Valeant Pharmaceuticals Intl by 110.1% in the third quarter.
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. For the quarter, shares have been noted at -25.00%. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).